SPL Medical announces achievement of next major clinical development milestone for its breakthrough platform product Ferrotran®: Now >75% patients included in Phase III trial

03 Aug SPL Medical announces achievement of next major clinical development milestone for its breakthrough platform product Ferrotran®: Now >75% patients included in Phase III trial

SPL medical has its proprietary iron-based nano-particle Ferrotran® (Ferumoxtran) product and platform in clinical Phase III. The pivotal trial named PROSTAPROGRESS has now reached the next major milestone by inclusion of over 75% of the patients into this trial.